drugset / Trial / NCT03882307

Levels of Interleukin-6 andTransforming Growth Factor Beta in HCV Patients Sera

NCT03882307

Phase 0 Unknown 40 enrolled Assiut University
RandomizedCrossoverDouble-blindTreatment

Summary

Hepatitis C virus (HCV) infection is associated with significant morbidity and mortality owing to progression of a high percentage (85%) of HCV infected patients to chronic hepatitis, which might lead to the development of liver cirrhosis or hepato cellular carcinoma.. Egypt has possibly the highest HCV prevalence in the world, 10-20% of the general population .

Timeline

Start
2022-10
Primary completion
2022-11
Completion
2022-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Daclatasvir Small molecule 60 mg Oral
Comparator Sofosbuvir Small molecule 400 mg Oral